Oscar Health Q2 2024 GAAP EPS $0.20 Beats $0.16 Estimate, Sales $2.219B Beat $2.155B Estimate
Portfolio Pulse from Benzinga Newsdesk
Oscar Health (NYSE:OSCR) reported Q2 2024 earnings per share (EPS) of $0.20, surpassing the analyst consensus estimate of $0.16 by 25%. The company also reported quarterly sales of $2.219 billion, beating the estimate of $2.155 billion by 2.99%. This marks a significant improvement from the same period last year, with EPS increasing by 385.71% and sales by 45.89%.
August 07, 2024 | 10:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oscar Health (NYSE:OSCR) reported Q2 2024 earnings per share (EPS) of $0.20, surpassing the analyst consensus estimate of $0.16 by 25%. The company also reported quarterly sales of $2.219 billion, beating the estimate of $2.155 billion by 2.99%. This marks a significant improvement from the same period last year, with EPS increasing by 385.71% and sales by 45.89%.
Oscar Health's strong Q2 2024 earnings and revenue performance, significantly beating analyst estimates and showing substantial year-over-year growth, are likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100